ABY-71A1

**ABY-71A1** is an investigational **IgG1 monoclonal antibody** being developed by **Abyssinia Biologics** for **Alzheimer's disease** and related amyloid-driven neurodegenerative conditions. Available public descriptions indicate that it was designed to bind **toxic soluble amyloid beta oligomers** with high specificity, supporting both potential **immunotherapeutic** use and use in ultra-sensitive **plasma and CSF diagnostic assays**. Public pipeline summaries characterize its target/mechanism under **APP beta amyloid A4 protein inhibition**, but the more precise biological description from company-linked materials is selective recognition of **oligomeric amyloid beta species** rather than generic inhibition of APP itself. Development appears to have remained **preclinical**, with no evidence of approval or commercial launch.

Other names

beta amyloid antagonist